Health
Canada report looks at painkiller prescriptions in Atlantic Canada
Although
it was Newfoundland and Nova Scotia that first raised alarms about
the abuse of so-called "hillbilly heroin" in Atlantic
Canada, it is New Brunswick that accounts for most of the prescriptions
for the highly addictive painkiller oxycodone, according to a new
Health Canada report.
During the first six months
of 2005, more than 92,500 prescriptions were filled for oxycodone-based painkillers,
such as OxyContin, at 651 retail pharmacies throughout the four Atlantic provinces.
New Brunswick generated
44 per cent of those transactions, and had the highest number of oxycodone prescribers
in the region at 133 per 100,000 residents.
"It's interesting,"
said Enid Harrison, spokeswoman for the Ottawa-based Canadian Centre on Substance
Abuse. "They weren't identifying it as a problem in their province, specifically."
Prince Edward Island accounted
for only nine per cent of prescriptions, but the region's least-populous province
had the second-highest number of prescribers per capita, with 128 per 100,000
residents.
And prescription users
in Prince Edward Island also had the highest volume of transactions, averaging
46 each. New Brunswick prescribers averaged 41 each.
Newfoundland and Labrador
and Nova Scotia, where the issue made headlines after several deaths were blamed
on oxycodone abuse, accounted for 21 per cent and 27 per cent of the transactions,
respectively.
Newfoundland had 114 prescribers per 100,000 residents; Nova Scotia the least
of all four Atlantic provinces, with 111.
Nova Scotia also had the lowest average number of transactions per prescriber,
at 24. But Harrison and Health Canada warned that the study offers only baseline
data, which means it's difficult to draw conclusions.
"Even if we knew across
the country how many prescriptions are being doled out, it doesn't tell us how
many are being used inappropriately," Harrison said.
The Health Canada report
points out that the results don't take into account provincial health profiles,
demographics or variances in pain management protocol or products. "Readers
who wish to interpret, extrapolate or benchmark the report's findings should
exercise caution," it says.
"The outcome of this
review of sales transactions cannot be used on its own to determine definitive
actions. Its purpose was to provide stakeholders with factual information to
contribute to their efforts." Information on oxycodone prescriptions is
not readily available from other regions for comparison. "This is the first
(such report) we've done at Health Canada," said Carolyn Sexauer, spokeswoman
for the department. She said the report was done in response to requests from
task forces in Newfoundland and Nova Scotia, adding that Health Canada has other
initiatives underway, including a guide for health professionals.
Harrison lauded the Health
Canada report for providing a baseline for Atlantic Canada, but there is no
consistent monitoring program across the country. "We're looking for it
to actually go beyond that, to a much more sophisticated model for monitoring
the use of pharmaceutical drugs."

|